Mesoblast Limited American Depositary Shares (MESO)

Mesoblast announced the successful commercial launch of Ryoncil®, the first FDA-approved mesenchymal stromal cell therapy, at healthcare conferences in New York. The company plans to expand the product into additional indications like adult SR-aGvHD and inflammatory bowel disease.

The global stem cell banking market is expected to reach a value of USD 18.65 Billion by 2031, growing at a CAGR of 18.30% during the forecast period. The market is driven by advancements in cryopreservation, increased application of stem cell treatments, and the trend of late parenting leading to interest in cord blood banking.

Several ASX-listed companies are experiencing share price declines today, including Argosy Minerals, Flight Centre, Mesoblast, and Telix Pharmaceuticals. The reasons range from operational suspensions, profit-taking, and fundraising activities.

Australian stocks closed higher on Wednesday, with the S&P/ASX 200 index rising 0.73%. Gains were led by the Gold, A-REITs, and IT sectors.

Mesoblast (MESO) skyrockets 208.2% year to date on encouraging progress with its pipeline candidates.